Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof
AssigneeSepracor Inc.
InventorsNancy M. Gray, James W. Young
Life of this patent
Estimating the term…
Abstract
Methods and compositions are disclosed utilizing the optically pure R-isomers of terodiline or of the hydroxylated derivatives of terodiline, These compounds are potent drugs for the treatment of urinary incontinence, obstructive pulmonary disease and such other conditions as are related to the compounds' activity as anticholinergic agents.
Claims35
A method of treating urinary incontinence in a human while substantially reducing adverse effects associated with the administration of racemic terodiline, comprising administering to said human a therapeutically effective amount of a compound selected from the group consisting of R-terodiline, 2R-N-tert-butyl-4-(4-hydroxyphenyl)-4-phenyl-2-butylamine, R-N-(2-hydroxymethyl-2-propyl)-4,4-diphenyl-2-butylamine, R-N-tert-butyl-4,4-diphenyl-4-hydroxy-2-butylamine, or pharmaceutically acceptable salts thereof, substantially free of the S-stereoisomer.
A method of treating urinary incontinence in a human comprising administering to said human a therapeutically effective amount of a compound selected from the group consisting of 2R-N-tert-butyl-4-(4-hydroxyphenyl)-4-phenyl-2-butylamine, R-N-(2-hydroxymethyl-2-propyl)-4,4-diphenyl-2-butylamine, R-N-tert-butyl-4,4-diphenyl-4-hydroxy-2-butylamine, or pharmaceutically acceptable salts thereof, substantially free of the 2S-stereoisomer.
A method of treating obstructive pulmonary disease in a human while substantially reducing adverse effects associated with the administration of racemic terodiline, comprising administering to said human a therapeutically effective amount of a compound selected from the group consisting of R-terodiline, 2R-N-tert-butyl-4-(4-hydroxyphenyl)-4-phenyl-2-butylamine, R-N-tert-butyl-4,4-diphenyl-4-hydroxy-2-butylamine, R-N-(2-hydroxymethyl-2-propyl)-4,4-diphenyl-2-butylamine, or pharmaceutically acceptable salts thereof, substantially free of the S-stereoisomer.
A method of treating obstructive pulmonary disease in a human comprising administering to said human a therapeutically effective amount of a compound selected from the group consisting of 2R-N-tert-butyl-4-(4-hydroxyphenyl)-4-phenyl-2-butylamine, R-N-tert-butyl-4,4-diphenyl-4-hydroxy-2-butylamine, and R-N-(2-hydroxymethyl-2-propyl)-4,4-diphenyl-2-butylamine, or pharmaceutically acceptable salts thereof, substantially free of the 2S-stereoisomer.
A pharmaceutical composition useful for the treatment of a disease selected from the group consisting of urinary incontinence and obstructive pulmonary disease, the composition comprising an effective amount of a compound selected from the group consisting of R-terodiline, 2R-N-tert-butyl-4-(4-hydroxyphenyl)-4-phenyl-2-butylamine, R-N-tert-butyl-4,4-diphenyl-4-hydroxy-2-butylamine, R-N-(2-hydroxymethyl-2-propyl)-4,4-diphenyl-2-butylamine, and pharmaceutically acceptable salts thereof, wherein said pharmaceutical composition comprises, at least in part, said hydroxylated derivatives of R-terodiline substantially free of its S-stereoisomer;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.